| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.99M | 138.41M | 140.93M | 137.17M | 115.80M | 93.52M |
| Gross Profit | 101.76M | 109.16M | 112.85M | 111.98M | 100.32M | 82.65M |
| EBITDA | 83.19M | 91.47M | 111.64M | 102.89M | 85.35M | 53.00M |
| Net Income | 2.50M | 6.63M | 20.61M | 19.14M | 17.62M | -1.93M |
Balance Sheet | ||||||
| Total Assets | 1.27B | 1.26B | 1.27B | 1.39B | 1.26B | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 7.12M | 6.82M | 1.28M | 4.02M | 7.21M | 5.51M |
| Total Debt | 728.66M | 653.59M | 624.19M | 704.65M | 579.86M | 607.62M |
| Total Liabilities | 767.41M | 700.57M | 661.89M | 744.20M | 625.91M | 643.15M |
| Stockholders Equity | 485.29M | 534.13M | 583.58M | 632.98M | 622.78M | 444.81M |
Cash Flow | ||||||
| Free Cash Flow | 18.63M | -25.07M | 58.39M | -79.66M | -132.69M | -184.27M |
| Operating Cash Flow | 72.50M | 70.05M | 68.44M | 76.54M | 68.97M | 34.52M |
| Investing Cash Flow | -86.67M | -45.94M | 67.62M | -137.25M | -194.66M | -223.67M |
| Financing Cash Flow | 16.23M | -21.89M | -143.79M | 62.41M | 127.70M | 192.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.30B | 33.28 | 2.77% | 6.76% | 3.74% | 77.82% | |
69 Neutral | $158.10M | 19.41 | 52.29% | 4.90% | 29.76% | 22.76% | |
69 Neutral | $548.98M | 30.55 | 10.55% | 7.40% | 0.68% | -1.34% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
62 Neutral | $421.38M | ― | -2.32% | 12.35% | 3.40% | -240.85% | |
56 Neutral | $1.12B | ― | -18.84% | 0.86% | 4.10% | 8.96% | |
50 Neutral | $476.40M | ― | 0.49% | 11.15% | 2.73% | -131.16% |
Global Medical REIT Inc. is a real estate investment trust specializing in acquiring and leasing healthcare facilities to physician groups and healthcare systems. In its third-quarter 2025 financial report, the company announced a net loss of $6.0 million, primarily due to a $6.3 million impairment charge on a facility in Aurora, IL, which was sold during the quarter. Despite this, the company reported a 4% year-over-year increase in both Funds from Operations (FFO) and Adjusted Funds from Operations (AFFO), with FFO at $14.5 million and AFFO at $16.2 million. Rental revenue rose by 8.4% to $37.0 million, driven by recent acquisitions. The company also completed a one-for-five reverse stock split and established a $50 million share repurchase program. Looking ahead, Global Medical REIT remains focused on optimizing its portfolio and maintaining high occupancy rates, with a 2025 AFFO guidance range of $4.50 to $4.60 per share.
Global Medical REIT Inc’s recent earnings call highlighted a cautiously optimistic sentiment, with effective management of debt maturities and notable growth in same-store NOI and leasing activities. Despite these positives, the company faces challenges such as limited acquisition capabilities due to high capital costs, a high payout ratio, and tenant credit concerns. Overall, the positives slightly outweigh the negatives, reflecting a balanced outlook for the company’s financial health.
On October 8, 2025, Global Medical REIT Inc. announced a third amended and restated credit facility with JPMorgan Chase Bank, extending the maturity dates of its $400 million revolver and $350 million term loan, now divided into three tranches maturing between 2029 and 2031. The amendment removes a previous credit spread adjustment and maintains the pricing grid and $500 million accordion feature, resulting in an increased weighted average debt term from 1.3 years to 4.4 years, potentially enhancing the company’s financial stability and operational flexibility.
The most recent analyst rating on (GMRE) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.
On September 18, 2025, Global Medical REIT Inc. implemented a one-for-five reverse stock split, reducing its authorized common stock from 500 million to 100 million shares. This adjustment, effective September 19, 2025, did not affect the company’s preferred stock or shareholders’ ownership percentages, except for minor changes due to fractional shares being settled in cash. The common stock will trade on a split-adjusted basis on the NYSE from September 22, 2025.
The most recent analyst rating on (GMRE) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.